203 related articles for article (PubMed ID: 6177955)
1. Coronary atherosclerosis and plasma lipoproteins: epidemiology and pathophysiologic considerations.
Miller NE
J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S190-5. PubMed ID: 6177955
[TBL] [Abstract][Full Text] [Related]
2. The emerging problem of plasma lipid changes during antihypertensive therapy.
Johnson BF
J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S213-21. PubMed ID: 6177959
[TBL] [Abstract][Full Text] [Related]
3. Atherosclerotic risk factors in cardiovascular disease.
LaRosa JC
J Reprod Med; 1986 Sep; 31(9 Suppl):906-12. PubMed ID: 3772910
[TBL] [Abstract][Full Text] [Related]
4. Effects of niceritrol (pentaerythritol tetranicotinate) on plasma lipoprotein concentration: increment of high density lipoprotein(HDL) cholesterol and HDL-cholesterol/low density lipoprotein cholesterol ratio in hypo-high density lipoproteinemia.
Oida K; Nakai T; Tamai T; Kutsumi Y; Kobayashi T; Hayashi T; Yamada S; Takeda R
Artery; 1982; 10(4):266-85. PubMed ID: 7181672
[TBL] [Abstract][Full Text] [Related]
5. [Disruption of the cholesterol-transport function of lipoproteins in the blood plasma of patients with ischemic heart disease].
Gerasimova EN; Perova NV; Kurdanov KhA; Polesskiĭ VA
Vopr Med Khim; 1984; 30(6):71-6. PubMed ID: 6528538
[TBL] [Abstract][Full Text] [Related]
6. Risks for hyperlipidemia.
Nestruck AC; Davignon J
Cardiol Clin; 1986 Feb; 4(1):47-56. PubMed ID: 2871933
[TBL] [Abstract][Full Text] [Related]
7. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group.
Connelly PW; Stachenko S; MacLean DR; Petrasovits A; Little JA
Can J Cardiol; 1999 Apr; 15(4):419-27. PubMed ID: 10322251
[TBL] [Abstract][Full Text] [Related]
8. Reduction of low density and high density lipoprotein cholesterol by fat-modified diets. A survey of recent findings.
Vessby B; Lithell H; Boberg J
Hum Nutr Clin Nutr; 1982; 36(3):203-11. PubMed ID: 6749766
[TBL] [Abstract][Full Text] [Related]
9. [Various lipoprotein fractions and their relation to ischemic heart disease].
Palazzuoli V; Mondillo S; Kristodhullu A; De Stefano R; Amatucci G
G Ital Cardiol; 1983; 13(2):90-4. PubMed ID: 6884650
[TBL] [Abstract][Full Text] [Related]
10. Antihypertensive therapy and the risk of coronary heart disease.
Ames RP; Hill P
J Cardiovasc Pharmacol; 1982; 4 Suppl 2():S206-12. PubMed ID: 6177958
[TBL] [Abstract][Full Text] [Related]
11. [High-density lipoproteins in children with coronary diseases].
Oberhänsli I; Pometta D; Micheli H; Raymond L
Helv Paediatr Acta; 1981; 36(2):135-47. PubMed ID: 7251385
[TBL] [Abstract][Full Text] [Related]
12. Effect of mepindolol on serum lipids.
Martignoni A; Perani G; Finardi G; Mastropasqua E; Fogari R
Int J Clin Pharmacol Ther Toxicol; 1982 Nov; 20(11):543-5. PubMed ID: 7174157
[TBL] [Abstract][Full Text] [Related]
13. Inverse relationship of serum LDL cholesterol and the LDL/HDL cholesterol ratio to liver microsomal enzyme induction in man.
Luoma PV; Sotaniemi EA; Pelkonen RO
Res Commun Chem Pathol Pharmacol; 1983 Oct; 42(1):173-6. PubMed ID: 6648042
[TBL] [Abstract][Full Text] [Related]
14. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
Gotto AM
Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
[TBL] [Abstract][Full Text] [Related]
15. Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics.
Luoma PV; Sotaniemi EA; Arranto AJ
Scand J Clin Lab Invest; 1983 Dec; 43(8):671-5. PubMed ID: 6665516
[TBL] [Abstract][Full Text] [Related]
16. Lipoproteins, cardiovascular disease, and death. The Framingham study.
Gordon T; Kannel WB; Castelli WP; Dawber TR
Arch Intern Med; 1981 Aug; 141(9):1128-31. PubMed ID: 7259370
[TBL] [Abstract][Full Text] [Related]
17. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
18. Differential changes in plasma high-density lipoprotein-cholesterol levels in obese men and women during weight reduction.
Brownell KD; Stunkard AJ
Arch Intern Med; 1981 Aug; 141(9):1142-6. PubMed ID: 7259372
[TBL] [Abstract][Full Text] [Related]
19. Correlates and consequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group.
Wilt TJ; Rubins HB; Collins D; O'Connor TZ; Rutan GH; Robins SJ
Arch Intern Med; 1996 Jun; 156(11):1181-8. PubMed ID: 8639012
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group.
Connelly PW; Petrasovits A; Stachenko S; MacLean DR; Little JA; Chockalingam A
Can J Cardiol; 1999 Apr; 15(4):428-33. PubMed ID: 10322252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
